Vergent Bioscience is a groundbreaking brand in the field of tumor visualization. They are dedicated to enhancing surgeons' ability to visualize tumors during surgery, ultimately leading to more successful outcomes for both surgeons and patients. With a focus on minimally invasive and robotic-assisted surgery, Vergent aims to unlock the full potential of these procedures by significantly improving tumor visibility.

To achieve this, Vergent is developing tumor-targeted agents that enhance intraoperative tumor visualization. Their lead program, VGT-309, is a targeted fluorescent-imaging agent currently being evaluated in a Phase 2 clinical study at the University of Pennsylvania for lung cancer surgeries. Combining innovative imaging agents, rigorous scientific research, and a world-class leadership team, Vergent Bioscience is on track to become the global leader in intraoperative cancer surgery.

With their cutting-edge technology and commitment to advancing the field, Vergent is revolutionizing the way cancer surgery is conducted. Contact Vergent Bioscience today to learn more about their groundbreaking contributions to the field of tumor visualization